VC005 tablets for people with non-segmental vitiligo
Official title: A Multicenter, Randomized, Double-blind, Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Non-segmental Vitiligo
Run by Jiangsu vcare pharmaceutical technology co., LTD · NCT07172347 · Data updated 2026-11-12
This trial will test VC005 tablets to see if they safely help adults aged 18–70 with non-segmental vitiligo regain skin pigment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 120 (estimated) |
| Sponsor | Jiangsu vcare pharmaceutical technology co., LTD Industry-sponsored |
| Locations | 1 site (Beijing, Beijng) |
| Status | Recruiting |
| Started | October 31, 2025 |
| Main results expected | August 30, 2027 |
| Study ends | August 30, 2027 |
| Registry record updated | January 2, 2026 |
| Trial ID | NCT07172347 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–70 with non-segmental vitiligo who can give informed consent, are not pregnant or lactating, and have no history of depigmentation treatment or recent experimental drug/device participation.
✕Probably not a fit
People who are pregnant or lactating, have complete whitening of facial hair in the affected areas, are allergic to VC005 ingredients, or previously underwent depigmentation treatment are unlikely to benefit from this trial.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a multicenter, randomized, double-blind, placebo-controlled Phase II study comparing VC005 tablets to matching placebo in adults with non-segmental vitiligo. Participants aged 18–70 will be randomly assigned to receive VC005 or placebo and followed for efficacy and safety outcomes. Key exclusions include pregnancy or lactation, complete whitening of facial hair in the vitiligo area, known allergy to VC005 ingredients, prior depigmentation treatments, and recent participation in other experimental drug or device trials. The study will monitor skin repigmentation measures and adverse events to characterize both benefit and tolerability.
Why it matters
Potential benefit: If successful, VC005 could help restore pigment and improve appearance and quality of life for people with non-segmental vitiligo.
How similar studies have gone: Other oral and topical approaches for vitiligo have shown mixed but sometimes promising results in early-phase trials, so this oral agent has some rationale but is not yet proven.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol. * The subject is between 18 and 70 years of age (including borderline values) , regardless of gender. Exclusion Criteria: * Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period. * All hair in the vitiligo area on the face is white. * Those who are known or suspected to be allergic to the main ingredients and excipients of VC005 or similar drugs. * Subjects who have previously received depigmentation treatment. * Subjects who have received experimental drug administration or participated in device clinical trials within the first month or 5 half lives (whichever is longer) prior to randomization.
Where it's running
-
The Peking University People's Hospital
Beijing, Beijng, China Recruiting
Study contacts
- Study coordinator: xiaojuan lai
- Email: lai_xiaojuan@vcarepharmatech.com
- Phone: 15358160458
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Test of ACT-777991 in adults with non-segmental vitiligo
This study tests whether ACT-777991 can help restore skin color in adults with non-segmental vitiligo, compared to placebo.
-
Different doses of GIA632 for adults with non-segmental vitiligo
This trial tests whether different doses of GIA632 can safely help restore skin pigment in adults with non-segmental vitiligo.
-
SHR0302 tablets with or without SHR0302 base gel for non-segmental vitiligo
This trial will test whether SHR0302 tablets, alone or together with an SHR0302 base gel, help adults with non-segmental vitiligo and are safe to use.
-
Phase 2 EI-001 for non-segmental vitiligo
This trial will test whether the antibody drug EI-001 can help adults (18–65) with non‑segmental vitiligo regain skin pigment more than a placebo.
-
Roflumilast 0.3% foam for children with non-segmental vitiligo
This trial will try a roflumilast 0.3% topical foam to see if it helps children and teens (ages 2–17) with non-segmental vitiligo affecting small areas including the face.
-
ICP-332 treatment for non-segmental vitiligo
This trial will test whether oral ICP-332 tablets help people with non-segmental vitiligo (including adolescents in the Phase III part) who have at least 5% body surface area affected and facial involvement regain skin pigment better than placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.